These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 7802634

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cellular cholesterol efflux in macrophages.
    Li Q, Tsujita M, Yokoyama S.
    Biochemistry; 1997 Oct 07; 36(40):12045-52. PubMed ID: 9315842
    [Abstract] [Full Text] [Related]

  • 5. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
    Holvoet P, Danloy S, Deridder E, Lox M, Bernar H, Dhoest A, Collen D.
    J Clin Invest; 1998 Jul 15; 102(2):379-85. PubMed ID: 9664079
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
    Moghadasian MH, McManus BM, Nguyen LB, Shefer S, Nadji M, Godin DV, Green TJ, Hill J, Yang Y, Scudamore CH, Frohlich JJ.
    FASEB J; 2001 Dec 15; 15(14):2623-30. PubMed ID: 11726538
    [Abstract] [Full Text] [Related]

  • 14. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux.
    Lee M, Calabresi L, Chiesa G, Franceschini G, Kovanen PT.
    Arterioscler Thromb Vasc Biol; 2002 Sep 01; 22(9):1475-81. PubMed ID: 12231569
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity.
    Rosenblat M, Volkova N, Aviram M.
    Biofactors; 2011 Sep 01; 37(6):462-7. PubMed ID: 22162319
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-oxidant and anti-atherogenic properties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice.
    Rosenblat M, Volkova N, Coleman R, Aviram M.
    Atherosclerosis; 2007 Dec 01; 195(2):e61-8. PubMed ID: 17588583
    [Abstract] [Full Text] [Related]

  • 20. The effect of proatherogenic microbes on macrophage cholesterol homeostasis in apoE-deficient mice.
    Tuomainen AM, Hyvärinen K, Ehlers PI, Mervaala E, Leinonen M, Saikku P, Kovanen PT, Jauhiainen M, Pussinen PJ.
    Microb Pathog; 2011 Sep 01; 51(3):217-24. PubMed ID: 21421042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.